MD Biosciences Blog

The Minnesota Clinical Research Hub has announced its first contract win for a Phase I multi-site clinical trial with a large European plasma biotherapetuics company in combination with two of its founding members, MD Biosciences and Prism Research. See the associated press release on Business Wire.

About the MCRH

The Minnesota Clinical Research Hub (MCRH) is a partnership of five leading companies in the Minnesota health industry collaborating to provide a comprehensive clinical development platform. Leveraging their collective expertise, Prism Research, Medtronic, Center for Diagnostic Imaging (CDI), ThreeWire and MD Bioscience provide life science companies and local clinicians with a seamless partnership ensuring a responsive, integrated approach to clinical study conduct. Further information is available at www.mncrh.com.

About Prism Research

Prism Research is a 52-bed clinical research company specializing in the execution and management of phase 1/2a studies in patient and healthy populations with an emphasis on complex study designs. Since 2005, Prism Research has provided FDA approved investigational pharmaceutical and medical device testing services for drug and device manufacturers, academic institutions and private physicians as well as other researchers across Minnesota, the U.S. and abroad. Further information is available at www.prismresearchinc.com.

About MD Biosciences

MD Biosciences is a pharmaceutical, biotechnology and diagnostics development company providing research services and advanced diagnostic capabilities to the clinical and pre-clinical research markets. As a CLIA-certified diagnostic laboratory, MD Biosciences offers a wide array of molecular, proteomic and cellular analyses across multiple sample types with biomarker experts experienced in the development and validation of custom fit-for-purpose assays. With an emphasis on inflammation, immunology, oncology, neurology, metabolic disease and pain, MD Biosciences supports the design, development and implementation of diagnostic tests for patient selection and stratification.

MD Biosciences is proud to announce the launch of Salspera, LLC (www.salspera.com) to advance Saltikva® (MDB401B), a microbial-based immunotherapeutic product targeting cancer, towards regulatory approval. The Salspera team is actively preparing the next clinical study phase following the successful completion of Phase 1 human safety studies. Saltikva® has been presented at high level meetings, including the most recent conference held at the NIH National Cancer Institute. Next generation programs are also advancing through the preclinical pipeline, with the goal of providing a robust palette of specialized attenuated Salmonella-based guided therapies addressing patient needs with personalized “cocktails” and adjunct therapies.

Saint Paul, MN, April 20, 2017     Five leading research organizations have partnered to provide the most comprehensive clinical development platform in the industry. Leveraging their collective expertise, the Center for Diagnostic Imaging (CDI), Medtronic, MD Biosciences, Prism Research, and ThreeWire, have come together to make it easier for life science companies and clinicians to bring lifesaving and life improving products to patients in need. Dubbed the Minnesota Clinical Research Hub, this partnership provides sponsors with a flexible platform for conducting their trials, allowing use of the partners individually and collectively as research needs dictate. Contact MD Biosciences for more details about the MCRH and activities.

About MD Biosciences

MD Biosciences is a research and development company founded in 1991 with four business divisions. MD Biosciences CLIA laboratory provides assay development and clinical testing services for clinical stage programs. MD Biosciences Preclinical Services provide contract research services for drug development in areas including immuno-oncology, CNS, inflammatory and metabolic diseases. Early stage compounds in the area of neuropathic pain and cancer are being developed through MD Biosciences Innovalora Ltd. Finally, MD Biosciences is a manufacturer and distributor of proprietary products for industrial and academic drug discovery laboratories.

 MD Biosciences will be presenting its newest advances in translational pig models for pain at this year's SMi Pain Therapeutics Conference to be held in London, UK on May 22-23. Translational models in pigs for the study of pain have become an indispensable tool in drug development. The skin structure of the pig, particularly with respect to its neuronal structure, shows a high degree of similarity to that of humans. This provides a platform in which new therapeutics can be tested to yield results which are highly predictive of human outcomes. MD Biosciences has continuously developed its models to approximate the human condition as closely as possible, bringing its unique capabilities to the drug development process. Please contact MD Biosciences or SMi Group Ltd for conference details.

MD Biosciences Expands Histology and IHC Capabilities

New laboratories serving growing activity on clinical assay development and analysis front

About MD Biosciences

MD Biosciences is a research and development company founded in 1991 with four business divisions. MD Biosciences CLIA laboratory provides assay development and clinical testing services for clinical stage programs. MD Biosciences Preclinical Services provide contract research services for drug development in areas including immuno-oncology, CNS, inflammatory and metabolic diseases. Early stage compounds in the area of neuropathic pain and cancer are being developed through MD Biosciences Innovalora Ltd. Finally, MD Biosciences is a manufacturer and distributor of proprietary products for industrial and academic drug discovery laboratories.

Contact: Jane Smith

MD Biosciences Inc.
1 Imation Way          
Oakdale, MN 55128
Toll Free: 888-876-3246 or 651-641-2881
Email